461 related articles for article (PubMed ID: 22915465)
21. Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections.
Tacconelli E; Cataldo MA; Mutters NT; Carrara E; Bartoloni A; Raglio A; Cauda R; Mantengoli E; Luzzaro F; Pan A; Beccara LA; Pecile P; Tinelli M; Rossolini GM
Int J Antimicrob Agents; 2019 Jul; 54(1):49-54. PubMed ID: 30986523
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J;
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145
[TBL] [Abstract][Full Text] [Related]
23. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
[TBL] [Abstract][Full Text] [Related]
24. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
Harris PN; Tambyah PA; Paterson DL
Lancet Infect Dis; 2015 Apr; 15(4):475-85. PubMed ID: 25716293
[TBL] [Abstract][Full Text] [Related]
25. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
Gutiérrez-Gutiérrez B; Bonomo RA; Carmeli Y; Paterson DL; Almirante B; Martínez-Martínez L; Oliver A; Calbo E; Peña C; Akova M; Pitout J; Origüen J; Pintado V; García-Vázquez E; Gasch O; Hamprecht A; Prim N; Tumbarello M; Bou G; Viale P; Tacconelli E; Almela M; Pérez F; Giamarellou H; Cisneros JM; Schwaber MJ; Venditti M; Lowman W; Bermejo J; Hsueh PR; Mora-Rillo M; Gracia-Ahulfinger I; Pascual A; Rodríguez-Baño J;
J Antimicrob Chemother; 2016 Jun; 71(6):1672-80. PubMed ID: 26907184
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae blood isolates with inducible AmpC β-lactamase.
Cheong HS; Ko KS; Kang CI; Chung DR; Peck KR; Song JH
Microb Drug Resist; 2012 Aug; 18(4):446-52. PubMed ID: 22409779
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
[TBL] [Abstract][Full Text] [Related]
28. Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Zahar JR; Lesprit P; Ruckly S; Eden A; Hikombo H; Bernard L; Harbarth S; Timsit JF; Brun-Buisson C;
Int J Antimicrob Agents; 2017 Jan; 49(1):67-73. PubMed ID: 27890442
[TBL] [Abstract][Full Text] [Related]
29. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs).
Paterson DL
Clin Microbiol Infect; 2000 Sep; 6(9):460-3. PubMed ID: 11168179
[TBL] [Abstract][Full Text] [Related]
30. Carbapenems versus beta-lactam/beta-lactamase inhibitors to treat ESBL-producing Enterobacteriaceae infections.
Bru JP; Alfandari S; Bleibtreu A; Chavanet P; Gauzit R; Lescure X; Lesprit P; Tattevin P
Med Mal Infect; 2020 Jun; 50(4):313-315. PubMed ID: 31623961
[No Abstract] [Full Text] [Related]
31. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units.
Chiu S; Huang YC; Lien RI; Chou YH; Lin TY
Acta Paediatr; 2005 Nov; 94(11):1644-9. PubMed ID: 16303704
[TBL] [Abstract][Full Text] [Related]
32. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
Huang SS; Lee MH; Leu HS
J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
[TBL] [Abstract][Full Text] [Related]
33. Associated factors and outcomes for OXA-232 Carbapenem-resistant Enterobacteriaceae infections in a tertiary care centre in Mexico City: A case-control-control study.
Torres-González P; Ortiz-Brizuela E; Cervera-Hernandez ME; Bobadilla-Del Valle M; Martínez-Gamboa A; Sifuentes-Osornio J; Ponce-de-Leon A
Diagn Microbiol Infect Dis; 2016 Oct; 86(2):243-8. PubMed ID: 27519297
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases.
Qureshi ZA; Paterson DL; Peleg AY; Adams-Haduch JM; Shutt KA; Pakstis DL; Sordillo E; Polsky B; Sandkovsky G; Bhussar MK; Doi Y
Clin Microbiol Infect; 2012 Sep; 18(9):887-93. PubMed ID: 21951551
[TBL] [Abstract][Full Text] [Related]
35. Carbapenem-resistant enterobacteriaceae: an emerging problem in children.
Logan LK
Clin Infect Dis; 2012 Sep; 55(6):852-9. PubMed ID: 22700827
[TBL] [Abstract][Full Text] [Related]
36. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
Palacios-Baena ZR; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina Gil-Bermejo J; Hernández A; Venditti M; Prim N; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Paño-Pardo JR; Torre-Cisneros J; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual Á; Rodríguez-Baño J;
Clin Infect Dis; 2017 Oct; 65(10):1615-1623. PubMed ID: 29020250
[TBL] [Abstract][Full Text] [Related]
37. Comparing the therapeutic efficacies of third-generation cephalosporins and broader-spectrum β-lactams as appropriate empirical therapy in adults with community-onset monomicrobial Enterobacteriaceae bacteraemia: a propensity score matched analysis.
Lee CH; Hsieh CC; Hong MY; Hung YP; Ko WC; Lee CC
Int J Antimicrob Agents; 2017 May; 49(5):617-623. PubMed ID: 28315452
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bahrain.
Bindayna KM; Senok AC; Jamsheer AE
J Infect Public Health; 2009; 2(3):129-35. PubMed ID: 20701872
[TBL] [Abstract][Full Text] [Related]
39. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis.
Rottier WC; Ammerlaan HS; Bonten MJ
J Antimicrob Chemother; 2012 Jun; 67(6):1311-20. PubMed ID: 22396430
[TBL] [Abstract][Full Text] [Related]
40. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Nguyen HM; Shier KL; Graber CJ
J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
